newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

  • Instil Bio, Inc. reported third quarter 2025 financial results & provided a corporate update on November 13, 2025.
  • In September, collaborator ImmuneOnco presented updated data for AXN-2510 monotherapy in relapsed/refractory squamous non-small cell lung cancer at the 2025 World Conference on Lung Cancer.
  • In October, subsidiary Axion Bio dosed the first patient in a Phase 1 trial of AXN-2510 monotherapy for relapsed or refractory solid tumors.
  • As of September 30, 2025, total cash, equivalents, restricted cash, marketable securities, & long-term investments totaled $83.4 million, compared to $115.1 million as of December 31, 2024.
  • Instil expects its current cash resources to fund operations beyond 2026.
  • Research & development expenses were $9.1 million for the three months ended September 30, 2025, & $21.2 million for the nine months ended September 30, 2025.
  • General & administrative expenses were $5.9 million for the three months ended September 30, 2025, & $21.2 million for the nine months ended September 30, 2025.
  • Restructuring & impairment charges were nil for the three months ended September 30, 2025, & $16.6 million for the nine months ended September 30, 2025.
  • Net loss per share was $2.01 for the three months ended September 30, 2025, & $9.53 for the nine months ended September 30, 2025.
  • Non-GAAP net loss per share was $1.75 for the three months ended September 30, 2025, & $5.95 for the nine months ended September 30, 2025.
  • Instil Bio is a clinical-stage biopharmaceutical company developing AXN-2510, a PD-L1xVEGF bispecific antibody for multiple solid tumors.